Hugues Lecat Appointed Chairman And Chief Executive Officer Of The Management Board Of Ethypharm

Hugues Lecat Appointed Chairman And Chief Executive Officer Of The Management Board Of Ethypharm

St Cloud, February, 10th, 2010 -M. Hugues Lecat has been appointed Chairman and CEO of the Management Board of the pharmaceutical company Ethypharm.

Hugues Lecat, 53, graduated from the Ecole Superieure de Commerce in Rouen and holds an MBA from INSEAD.

He has a vast experience in various functions such as finance, marketing, management in the Healthcare industry, and has held major positions with Medtronic, Rhone-Poulenc Rorer, Aventis, and Sanofi-aventis. More recently, he was Chief Executive Officer of Cooper, the pharmaceutical company specialized in OTC products.

Hugues Lecat, who succeeds to M. Olivier Thiberge, will carry on with the objective of making Ethypharm the worldwide privileged partner of pharmaceutical companies for the life cycle management of their drugs. 

About d'Ethypharm

Ethypharm is one of the leading pharmaceutical companies dedicated to the development of innovative medicines. Its patented technologies offer multiple benefits for patients by improving efficacy, administration, compliance, and reducing side-effects.

Ethypharm provides its clients with solutions for the life cycle management of their drugs. The company has one of the broadest portfolio of technologies to become the worldwide privileged partner of pharmaceutical companies. Ethypharm offers customized solutions for the development of the medicines of the future.

Caroline Guinet Communication Corporate 194 bureaux de la Colline 92213 ST Cloud Cedex +33.1.41.12.32.82 +33.6.30.51.25.27

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.